CXCL13 in laboratory diagnosis of Lyme neuroborreliosis-the performance of the recomBead and ReaScan CXCL13 assays in human cerebrospinal fluid samplesVisa övriga samt affilieringar
2022 (Engelska)Ingår i: European Journal of Clinical Microbiology and Infectious Diseases, ISSN 0934-9723, E-ISSN 1435-4373, Vol. 41, nr 1, s. 175-179Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
The chemokine CXCL13 is used as complement to serology in the diagnostics of Lyme neuroborreliosis (LNB). We evaluated and compared the semi-quantitative, cassette-based ReaScan CXCL13 assay with the quantitative recomBead CXCL13 assay using a collection of 209 cerebrospinal fluid samples. The categorical agreement between results interpreted as negative, grey zone, and positive by the two methods was 87%. The diagnostic sensitivity was higher using the recomBead assay, whereas specificity was higher using ReaScan. Few manual steps, and a short turn-around time with no batching of samples makes the ReaScan CXCL13 assay an attractive complement to serology in the diagnostics of LNB.
Ort, förlag, år, upplaga, sidor
Springer, 2022. Vol. 41, nr 1, s. 175-179
Nyckelord [en]
CXCL13, Diagnostics, Lyme neuroborreliosis, ReaScan, recomBead
Nationell ämneskategori
Infektionsmedicin
Identifikatorer
URN: urn:nbn:se:oru:diva-94879DOI: 10.1007/s10096-021-04350-yISI: 000705823200001PubMedID: 34626256Scopus ID: 2-s2.0-85116568394OAI: oai:DiVA.org:oru-94879DiVA, id: diva2:1601889
Forskningsfinansiär
Europeiska kommissionen
Anmärkning
Funding agency:
Interreg North Sea Region Programme J-No: 38-2-7-19
2021-10-112021-10-112025-04-01Bibliografiskt granskad